Plasma ADAMTS-13 protein is not associated with portal hypertension or hemodynamic changes in patients with cirrhosis
- 1 April 2016
- journal article
- research article
- Published by Elsevier in Digestive and Liver Disease
- Vol. 48 (4) , 404-408
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk (NNF11OC1015075)
This publication has 13 references indexed in Scilit:
- Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosisLiver International, 2014
- Extracellular matrix degradation in liver fibrosis: Biochemistry and regulationBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2013
- Hyperbilirubinemia interferes with ADAMTS‐13 activity measurement by FRETS‐VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathiesJournal of Thrombosis and Haemostasis, 2007
- Increased ADAMTS‐13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivoJournal of Thrombosis and Haemostasis, 2006
- FRETS‐VWF73, a first fluorogenic substrate for ADAMTS13 assayBritish Journal of Haematology, 2005
- Central and noncentral blood volumes in cirrhosis: relationship to anthropometrics and genderAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2003
- Changes in health and disease of the metalloprotease that cleaves von Willebrand factorBlood, 2001
- Arterial compliance in patients with cirrhosis: stroke volume-pulse pressure ratio as simplified indexAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2001
- Tissue Inhibitor of Metalloproteinases–1 Promotes Liver Fibrosis Development in A Transgenic Mouse ModelHepatology, 2000
- Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liverGastroenterology, 1996